Fig. 4: Cross cancer analysis to identify the pleiotropic DM CpGs between breast cancer (BrCa) and prostate cancer (PrCa). | Communications Biology

Fig. 4: Cross cancer analysis to identify the pleiotropic DM CpGs between breast cancer (BrCa) and prostate cancer (PrCa).

From: Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers

Fig. 4

a Venn overlap of i-MeWAS results using BrCa and PrCa meta-analysed GWAS-SS (BrCa+PrCa i-MeWAS), differential methylation results of tumour vs NAT in BrCa (BrCa TN-DM), and differential methylation results of tumour vs NAT in PrCa (PrCa TN-DM). b Venn overlap of independent i-MeWAS results using BrCa GWAS-SS (BrCa i-MeWAS) and PrCa GWAS-SS (PrCa i-MeWAS), and independent differential methylation results of tumour vs NAT in BrCa (BrCa TN-DM) and PrCa (PrCa TN-DM). i-MeWAS, imputation-based methylome-wide association study.

Back to article page